Journal of Clinical and Preventive Cardiology

REVIEW ARTICLE
Year
: 2016  |  Volume : 5  |  Issue : 4  |  Page : 125--129

Low density lipoprotein cholesterol reduction for the prevention of cardiovascular disease: Newer concepts


Shamanna S Iyengar 
 Department of Cardiology, Manipal Hospital, Bengaluru, Karnataka, India

Correspondence Address:
Shamanna S Iyengar
Manipal Hospital, Bengaluru, Karnataka
India

Low density lipoprotein cholesterol (LDL-C) is the target of lipid lowering therapy in subjects who have atherosclerotic cardiovascular disease (ASCVD) or who are at risk of developing it. There have been many debatable issues in this field. Should lifelong statins be prescribed for subjects at low risk of ASCVD in primary prevention? How low one can go in LDL-C lowering and is it safe? Should we «DQ»treat to target«DQ» or just administer high or moderate or low intensity statins based on the risk category? What is the role of nonstatin drugs in lipid lowering therapy? Are proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9 inhibitors) going to be the game changers? There is an abundance of literature looking at these matters. Statins continue to be the first choice in dyslipidemia management. PCSK9 inhibitors would be a welcome addition to the armamentarium or an attractive alternative in certain situations.


How to cite this article:
Iyengar SS. Low density lipoprotein cholesterol reduction for the prevention of cardiovascular disease: Newer concepts.J Clin Prev Cardiol 2016;5:125-129


How to cite this URL:
Iyengar SS. Low density lipoprotein cholesterol reduction for the prevention of cardiovascular disease: Newer concepts. J Clin Prev Cardiol [serial online] 2016 [cited 2022 Jan 27 ];5:125-129
Available from: https://www.jcpconline.org/article.asp?issn=2250-3528;year=2016;volume=5;issue=4;spage=125;epage=129;aulast=Iyengar;type=0